Atenolol or Propranolol

Phase 2Small molecule

NNational Taiwan University Hospital

Atenolol or Propranolol is one of 6 small molecule programs targeting Marfan syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Marfan SyndromeActive, not recruiting

Marfan SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Marfan Syndrome

#DrugCompanyPhaseTrials

Avapro

Calan

1 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—4

Aceon

Institut de Recherches Internationales Servier

Phase 3

1 5

Coversyl

SServier

Phase 3

1 6

Atenolol or Propranolol

NNational Taiwan University Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Marfan syndrome1 trial

A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome

Unknown status·NNational Taiwan University Hospital·Phase 2·NCT00651235·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atenolol or Propranolol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atenolol or Propranolol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atenolol or Propranolol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Taiwan University Hospital

Atenolol or Propranolol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Marfan syndrome1 trial

References

Drug Info

Quick Facts

Related News